ERNA

Ernexa Therapeutics Inc.
CAPPED RATING

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Ernexa Therapeutics Inc. (ERNA) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (F). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
F
Factor Score 0.6 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.2
EV / EBITDA 0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -54.5%
Price Return 12M -95.4%
Catalyst Signal 0.00
Market Cap $3.4M
TTM Revenue N/A
Price / Sales N/A
ROE -320.7%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) D+ (1.8) F (0.6) D- (0.8) C+ (2.6) C- (1.9)
2026-11-04 B+ (3.7) C- (1.9) F (0.7) D (1.2) C+ (2.7) C- (2.0)
2026-10-28 B+ (3.7) C- (1.9) F (0.7) D (1.3) C+ (2.7) C- (2.0)
2026-10-21 B+ (3.7) D+ (1.8) F (0.6) D (1.3) C+ (2.6) C- (2.0)
2026-10-14 B+ (3.7) D+ (1.8) F (0.6) D- (1.1) C+ (2.6) C- (2.0)
Page 1 of 5